Emgality® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Emgality® ▼ (galcanezumab): Concomitant Medications for Migraine Headache in Phase 3 Studies

Medications for the acute treatment of migraine headaches were allowed during phase 3 with restrictions for opiates, barbiturates, and injectable steroids.

Concomitant Medications for Migraine Headache in Phase 3 Studies

Galcanezumab has been studied in phase 3 randomized, double-blind, placebo-controlled studies in adult patients for the prevention of

  • episodic migraine (EVOLVE-1 and EVOLVE-2),1,2 and

  • chronic migraine (REGAIN).3

In addition, CONQUER was a phase 3 randomized double-blind, placebo-controlled study that assessed galcanezumab efficacy and safety in adult patients with episodic migraine or chronic migraine who had not benefited from multiple previous migraine preventive treatments.4

Medications Allowed for the Acute Treatment of Migraine Headaches or Other Pain or Injury

Medications for the acute treatment of migraine headaches or other pain or injury were allowed during phase 3 migraine prevention studies.5 These included

  • acetaminophen (paracetamol)

  • NSAIDs

  • triptans

  • ergotamine and derivatives

  • isometheptene mucate

  • dichloralphenazone and acetaminophen combination (Midrin), or

  • combinations thereof.5

Medications allowed with restrictions included

  • opioid and barbiturates no more than 3 days/month in the EVOLVE-1, EVOLVE-2, and REGAIN studies1-3

  • opioid and barbiturates no more than 4 days/month in the CONQUER study, and

  • single dose of injectable steroids only once during the study, in an emergency setting.5

Concomitant Usage of Acute Headache Medication in the Pivotal Migraine Prevention Studies (EVOLVE-1, EVOLVE-2, and REGAIN)

The majority of patients (≥93%) recorded concomitant use of ≥1 acute therapy in the

  • EVOLVE episodic migraine prevention studies (Table 1), and 

  • REGAIN chronic migraine prevention study (Table 2).5

The most frequently used concomitant medications (≥5%) included

  • ibuprofen, acetaminophen (paracetamol), Thomapyrin N, sumatriptan, and naproxen in EVOLVE-1

  • ibuprofen, acetaminophen (paracetamol), sumatriptan, Thomapyrin N, acetylsalicylic acid, naproxen, and ketorolac in EVOLVE-2, and

  • ibuprofen, acetaminophen (paracetamol), sumatriptan, Thomapyrin N, naproxen, and acetylsalicylic acid in REGAIN.5

Table 1. Summary of Concomitant Usage of Acute Therapya From ePRO Diary: EVOLVE-1 and EVOLVE-25

EVOLVE-1

Concomitant Therapy Classes from ePRO

PBO
N=433
n (%)

GMB 120mg
N=213
n (%)

GMB 240mg
N=212
n (%)

Subjects with ≥1 concomitant therapy from ePRO

413 (95.4)

199 (93.4)

205 (96.7)

NSAIDs/Aspirinb

346 (79.9)

157 (73.7)

172 (81.1)

Acetaminophen (paracetamol)b

255 (58.9)

103 (48.4)c

136 (64.2)d

Triptansb

198 (45.7)

95 (44.6)

70 (33.0)cd

Anti-nausea medicationb

20 (4.6)

8 (3.8)

4 (1.9)

Ergotsb

0 (0.0)

2 (0.9)

3 (0.7)

EVOLVE-2

Concomitant Therapy Classes from ePRO

PBO
N=461
n (%)

GMB 120mg
N=231
n (%)

GMB 240mg
N=223
n (%)

Subjects with ≥1 concomitant therapy from ePRO

446 (96.8)

215 (93.1)c

212 (95.1)

NSAIDs/Aspirinb

338 (73.2)

169 (73.2)

164 (73.5)

Acetaminophen (paracetamol)b

198 (43.0)

84 (36.4)

93 (41.7)

Triptansb

260 (56.4)

118 (51.1)

118 (52.9)

Anti-nausea medicationb

34 (7.4)

16 (6.9)

14 (6.3)

Ergotsb

14 (3.0)

3 (1.3)

3 (1.4)

Abbreviations: ePRO = electronic patient-reported outcomes; GMB = galcanezumab; NSAID = nonsteroidal anti-inflammatory drug; PBO = placebo.

a Summary by therapy class.

b As collected from ePRO diary.

c p<.05 vs PBO.

d p<.05 vs GMB 120 mg.

Table 2. Summary of Concomitant Usage of Acute Therapya From ePRO Diary: REGAIN5

Concomitant Therapy Classes from ePRO

PBO
N=558
n (%)

GMB 120mg
N=278
n (%)

GMB 240mg
N=277
n (%)

Subjects with ≥1 concomitant therapy from ePRO

536 (96.1)

268 (96.4)

266 (96.0)

NSAIDs/Aspirinb

426 (76.3)

200 (71.9)

192 (69.3)c

Triptansb

304 (54.5)

149 (53.6)

151 (54.5)

Acetaminophen (paracetamol) b

258 (46.2)

140 (50.4)

110 (39.7)d

Anti-nausea medicationb

56 (10.0)

21 (7.6)

29 (10.5)

Ergotsb

21 (3.8)

11 (4.0)

11 (4.0)

Abbreviations: ePRO = electronic patient-reported outcomes; GMB = galcanezumab; NSAID = nonsteroidal anti-inflammatory drug; PBO = placebo.

a Summary by therapy class.

b As collected from ePRO diary.

c p<.05 vs PBO.

d p<.05 vs GMB 120 mg.

Concomitant Usage of Acute Headache Medication in Patients With Previous Migraine Preventive Treatment Failures (CONQUER)

Similar to the pivotal phase 3 studies, in the CONQUER study more than 95% of patients used acute headache medication during the double-blind treatment phase. The incidence was slightly higher in the placebo group (99.6%) compared with galcanezumab (95.3%; p=.0057).5

The acute headache medication used by the greatest percentage of patients, sumatriptan, was also used in a significantly greater percentage of patients in the placebo group (42.6%) compared with galcanezumab (33.2%; p=.0439).5 The most frequently used acute medications (≥5%) in the galcanezumab group were sumatriptan, ibuprofen, acetaminophen (paracetamol), eletriptan, naproxen, rizatriptan, zolmitriptan, naratriptan, indomethacin, Thomapyrin N, metamizole, and nimesulide.

Therapeutic Indication

Galcanezumab is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.6

The recommended dose is 120 mg galcanezumab injected subcutaneously once monthly, with a 240 mg loading dose as the initial dose.6

References

1. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. http://dx.doi.org/10.1001/jamaneurol.2018.1212

2. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. http://dx.doi.org/10.1177/0333102418779543

3. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. http://dx.doi.org/10.1212/WNL.0000000000006640

4. Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814-825. http://dx.doi.org/10.1016/S1474-4422(20)30279-9

5. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

6. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

ePRO = electronic patient-reported outcomes

NSAID = nonsteroidal anti-inflammatory drug

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: July 22, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question